ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AEZS Aeterna Zentaris Inc

8.3885
0.00 (0.00%)
Pre Market
Last Updated: 12:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aeterna Zentaris Inc NASDAQ:AEZS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.3885 5.00 9.80 0 12:00:00

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Di...

11/12/2014 9:01pm

GlobeNewswire Inc.


Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Aeterna Zentaris Charts.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company") (Nasdaq:AEZS) securities between October 18, 2012 and November 5, 2014.

For more information, click here: http://zlk.9nl.com/aeterna-zentaris.

The complaint alleges that Aeterna Zentaris made false and/or misleading statements or failed to disclose that: (a) the planned analysis of the Company's macimorelin clinical trial failed to meet its primary efficacy endpoint; (b) insufficient data existed to confirm that the patients in the clinical trial were accurately diagnosed with Adult Growth Hormone Deficiency; (c) a serious cardiac event could have been attributed to macimorelin; and (d) as a result, the FDA would not approve the New Drug Application for macimorelin in its present form.

On November 6, 2014, the Company revealed that the FDA would not approve the macimorelin New Drug Application in its present form.

If you suffered a loss in Aeterna Zentaris you have until January 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/aeterna-zentaris.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits and have helped shareholders recover millions of dollars in losses over the years. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP
         Joseph Levi, Esq.
         Eduard Korsinsky, Esq.
         30 Broad Street - 24th Floor
         New York, NY 10004
         Tel: (212) 363-7500
         Toll Free:  (877) 363-5972
         Fax: (866) 367-6510
         www.zlk.com

1 Year Aeterna Zentaris Chart

1 Year Aeterna Zentaris Chart

1 Month Aeterna Zentaris Chart

1 Month Aeterna Zentaris Chart

Your Recent History

Delayed Upgrade Clock